Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Needham Downgrades Analog Devices to Hold

Needham Downgrades Analog Devices to Hold

Needham analyst Quinn Bolton downgrades Analog Devices (NASDAQ:ADI) from Buy to Hold.

byBenzinga Newsdesk

August 18, 2022

1 minute read

Needham analyst Quinn Bolton downgrades Analog Devices (NASDAQ:ADI) from Buy to Hold.

Alibaba’s Jack Ma and Joe Tsai Amplify Stakes, Sparking Stock Surge Amid Management Shakeup

By Anusuya Lahiri

January 24, 7:45 AM

Alibaba appoints new acting CEO for South Asian online retailer Daraz Group as part of management reshuffle, amid challenges and stock market boost.

BABA

Analyst Ratings

Expert Ratings for Tenaya Therapeutics

By Benzinga Insights

October 9, 8:00 AM

Tenaya Therapeutics (NASDAQ:TNYA) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

TNYA

TotalEnergies’ Strategy: CEO Reportedly Affirms France Listing While Eyeing US Markets

By Lekha Gupta

May 15, 8:19 AM

TotalEnergies SE will reportedly stay listed in France, but may offer shares to US shareholders due to higher valuation in US market.

TTE

Virpax Reports On Progress Of Envelta; Dose Ranging Studies For Envelta In Both Rats And Dogs Were Recently Completed, And The Intranasal Administration Of Envelta Was Well-Tolerated And No Adverse Effects Were Observed

By Happy Mohamed

April 5, 9:00 AM

Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress

VRPX

Needham Downgrades Analog Devices to Hold

Related Posts

Alibaba’s Jack Ma and Joe Tsai Amplify Stakes, Sparking Stock Surge Amid Management Shakeup

Expert Ratings for Tenaya Therapeutics

TotalEnergies’ Strategy: CEO Reportedly Affirms France Listing While Eyeing US Markets

Virpax Reports On Progress Of Envelta; Dose Ranging Studies For Envelta In Both Rats And Dogs Were Recently Completed, And The Intranasal Administration Of Envelta Was Well-Tolerated And No Adverse Effects Were Observed